High rates of kidney impairment among older people (≥ 60 years) living with HIV on first-line antiretroviral therapy at screening for a clinical trial in Kenya

PLoS One. 2023 Jun 23;18(6):e0285787. doi: 10.1371/journal.pone.0285787. eCollection 2023.

Abstract

Background: There is a paucity of data on kidney impairment among older people living with HIV (PLWH). We evaluated kidney function among PLWH age ≥ 60 years on first-line antiretroviral (ARV) therapy during screening for a clinical trial in Kenya.

Methods: The bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) Elderly Study is an open-label, randomized, active-controlled, non-inferiority trial conducted at two sites in Kenya. Potential participants were screened for study entry if they were at least 60 years old, had been on ARVs for at least 24 weeks and had no history of treatment failure. At screening, participants had samples collected for serum creatinine and estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration 2021 equation.

Results: Between January and April 2022, 714 participants were screened and had creatinine measured. All participants were black, 54.1% were female and the median age was 64 years (range 60 to 87 years). Most participants (666 [93.3%]) were on tenofovir disoproxil fumarate-containing regimens, 711 (99.6%) were on dolutegravir-containing regimens, and only 2 (0.3%) were on a regimen with a ritonavir-boosted protease inhibitor. Most participants (686 [96.6%]) were virally suppressed. Treatment for comorbidities was common, with 175 (24.5%) on treatment for hypertension and 39 (5.5%) on treatment for diabetes mellitus. The median eGFR was 64.7 mL/min/1.73m2, and 289 (40.5%) participants had an eGFR < 60 mL/min/1.73m2. In multivariate analysis, factors associated with lower eGFR were female gender (p<0.001), being on treatment for hypertension (p<0.001) and nadir CD4 count < 50 cells/μL (p = 0.008).

Conclusions: Our study identified high rates of impaired kidney function among elderly PLHW in Kenya, which highlights the importance of routine assessment of kidney function and the need to address modifiable risk factors, use of appropriate ARVs, and management of kidney disease in this population.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / therapeutic use
  • Aged
  • Aged, 80 and over
  • Alanine / therapeutic use
  • Anti-HIV Agents* / therapeutic use
  • Anti-Retroviral Agents / therapeutic use
  • Emtricitabine / therapeutic use
  • Female
  • HIV Infections* / complications
  • HIV Infections* / diagnosis
  • HIV Infections* / drug therapy
  • Humans
  • Kenya / epidemiology
  • Kidney
  • Male
  • Middle Aged
  • Tenofovir / therapeutic use

Substances

  • Emtricitabine
  • Adenine
  • Anti-Retroviral Agents
  • Tenofovir
  • Anti-HIV Agents
  • Alanine

Grants and funding

This work was supported through an investigator-initiated grant from Gilead Sciences to LAO (IN-EU-380-5765) and was sponsored by the University of Nairobi. The Ministry of Health Kenya and Gilead Sciences provided antiretroviral medications for the study. Gilead Sciences and the Ministry of Health Kenya had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.